Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Ancora Pharmaceuticals Awarded National Institute Of Health Grant For Continued Malaria Vaccine Research
With exciting pre-clinical results showing that its carbohydrate-based vaccine can combat cerebral malaria (CM), which causes inflammation of the brain, Ancora Pharmaceuticals has received another grant from the National Institute of Health (NIH) to research whether its vaccine candidate will also prevent severe malaria anemia (SMA).
generic viagra online
Lancet Articles Address Variety Of Global Health Issues
Health Community Should Welcome Human Rights Community"s Help With Reducing Maternal Deaths
plastic surgery before after
News of the day
Academic Physicians Who Spend Time On Their Most Meaningful Work Pursuits Appear To Have A Lower Risk Of Burnout
Faculty physicians at academic medical centers may be less likely to experience burnout if they spend at least one day per week on the aspect of their work that is most meaningful to them, according to a report in the May 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Sexual Health

ZymoGenetics Reports Encouraging Preliminary Results From Phase 2 Study Of IL-21 In Metastatic Melanoma Conducted By NCIC

ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that Interleukin 21 (IL-21) demonstrated an impressive overall response rate in the treatment of metastatic melanoma. In interim Phase 2 results from 24 patients, 29 percent showed a partial response, with an additional 33 percent of patients showing stable disease in this difficult to treat disease. "We are seeing promising anti-tumor response with IL-21 in patients with metastatic melanoma in this Phase 2 study," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics. "The response rate is favorable, particularly when compared to those of approved agents. Patients with advanced melanoma have few effective treatment options, so a clear need exists for new agents to manage this disease." Results from the Phase 2 clinical trial in patients with metastatic melanoma were presented at the World Congress on Melanoma meeting in Vienna, Austria. The single-agent multi-center clinical trial is being conducted by the NCIC Clinical Trials Group in Canada and is evaluating three dosing regimens of IL-21 in patients with no prior systemic therapy for metastatic melanoma. The primary endpoint is efficacy, as measured by objective response or lack of early disease progression. To date 7 of the 24 patients (29%) had a partial response (5 confirmed by RECIST criteria). Eight patients (33%) had stable disease. The most common adverse events were mild or moderate fatigue and rash. Two schedules testing 50 mcg/kg were evaluated in a total of 10 patients but were poorly tolerated due to adverse events including neutropenia and skin rash. The trial will be completed with a full cohort of 30 patients to be treated at the 30 mcg/kg dose, which is tolerable for outpatient dosing and active as assessed by tumor response. About Interleukin 21 (IL-21) IL-21, a cytokine that enhances CD8+ T cell and NK cell activity, has single-agent anti-tumor activity (J Clin Oncol 26:2034, 2008). ZymoGenetics has worldwide rights to IL-21 and is developing IL-21 for the treatment of renal cell carcinoma and metastatic melanoma. ZymoGenetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009